Trial Profile
A phase I trial of PTK787/ZK222584 [vatalanib] in combination with bevacizumab (Avastin) in patients with refractory and/or advanced malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2013
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary) ; Bevacizumab
- Indications Solid tumours
- Focus Adverse reactions
- 22 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2008 New trial record.